| Bid | 8.65 |
| Market Cap | 333.81M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.04 |
| PE Ratio (ttm) | -8.33 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 8.68 |
| Volume | 1,005,324 |
| Avg. Volume (20D) | 475,339 |
| Open | 8.85 |
| Previous Close | 8.57 |
| Day's Range | 8.21 - 9.19 |
| 52-Week Range | 8.21 - 29.70 |
| Beta | undefined |
About QTRX
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in variou...
Analyst Forecast
According to 4 analyst ratings, the average rating for QTRX stock is "Buy." The 12-month stock price forecast is $25, which is an increase of 188.52% from the latest price.
Next Earnings Release
Analysts project revenue of $35.55M, reflecting a 12.68% YoY growth and earnings per share of -0.22, making a -33.33% decrease YoY.
2 days ago · https://thefly.com
Quanterix price target lowered by $4 at TD Cowen, here's whyQuanterix + Akoya Biosciences +0.39 (+14.72%)
1 week ago · businesswire.com
David R. Walt Receives National Medal of Technology and InnovationBILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that David R. Walt, co-inven...
